Brokerages Expect bluebird bio Inc (BLUE) Will Announce Quarterly Sales of $10.33 Million

Analysts expect bluebird bio Inc (NASDAQ:BLUE) to report sales of $10.33 million for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for bluebird bio’s earnings, with estimates ranging from $5.00 million to $12.00 million. bluebird bio reported sales of $4.17 million in the same quarter last year, which indicates a positive year over year growth rate of 147.7%. The company is expected to report its next earnings report on Wednesday, February 20th.

According to Zacks, analysts expect that bluebird bio will report full-year sales of $44.08 million for the current year, with estimates ranging from $37.00 million to $48.00 million. For the next financial year, analysts expect that the firm will report sales of $72.89 million, with estimates ranging from $55.67 million to $121.59 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow bluebird bio.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($2.73) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.90) by $0.17. bluebird bio had a negative net margin of 1,326.02% and a negative return on equity of 31.50%. The business had revenue of $11.50 million during the quarter, compared to analysts’ expectations of $6.90 million. During the same quarter in the prior year, the company earned ($1.73) EPS. The firm’s quarterly revenue was up 49.2% on a year-over-year basis.

A number of analysts recently commented on BLUE shares. Cantor Fitzgerald set a $122.00 price objective on shares of bluebird bio and gave the company a “sell” rating in a research report on Wednesday, September 5th. ValuEngine upgraded shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 2nd. Piper Jaffray Companies cut shares of bluebird bio from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $240.00 to $120.00 in a research report on Thursday. Oppenheimer restated a “hold” rating on shares of bluebird bio in a research report on Tuesday, November 27th. Finally, William Blair restated a “buy” rating on shares of bluebird bio in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and seventeen have issued a buy rating to the company. bluebird bio presently has a consensus rating of “Buy” and an average price target of $194.80.

In other bluebird bio news, insider David Davidson sold 2,000 shares of the stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $121.05, for a total transaction of $242,100.00. Following the completion of the transaction, the insider now owns 30,905 shares in the company, valued at approximately $3,741,050.25. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director James Mandell sold 1,000 shares of the stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $150.77, for a total value of $150,770.00. Following the transaction, the director now owns 1,568 shares of the company’s stock, valued at approximately $236,407.36. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,490 shares of company stock valued at $2,901,186. Corporate insiders own 3.00% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Stratos Wealth Partners LTD. bought a new position in bluebird bio during the 3rd quarter worth about $106,000. Belpointe Asset Management LLC acquired a new position in shares of bluebird bio during the 3rd quarter worth about $110,000. NuWave Investment Management LLC boosted its stake in shares of bluebird bio by 10,811.1% during the 3rd quarter. NuWave Investment Management LLC now owns 982 shares of the biotechnology company’s stock worth $143,000 after buying an additional 973 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of bluebird bio by 635.0% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,154 shares of the biotechnology company’s stock worth $167,000 after buying an additional 997 shares during the last quarter. Finally, Tower Research Capital LLC TRC acquired a new position in shares of bluebird bio during the 2nd quarter worth about $201,000.

Shares of BLUE traded down $6.62 during trading hours on Monday, reaching $102.23. The stock had a trading volume of 1,024,569 shares, compared to its average volume of 690,709. bluebird bio has a 52 week low of $100.99 and a 52 week high of $236.17. The stock has a market cap of $5.95 billion, a P/E ratio of -13.26 and a beta of 2.37.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Featured Article: Stop Order

Get a free copy of the Zacks research report on bluebird bio (BLUE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply